Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends Ozurdex for diabetic eye condition

Draft guidance cites implant as option for patients with diabetic macular oedema

allergan ozurdex dexamethasoneThe National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the dexamethasone intravitreal implant for the treatment of diabetic macular oedema (DMO).

The preliminary recommendations cite the implant, marketed by Allergan as Ozurdex, as a treatment option in patients where the implant is to be used in an eye with an intraocular (pseudophakic) lens, or if their DMO does not respond to non-corticosteroid treatment.

It is additionally recommended if the latter aforementioned treatment is an unsuitable treatment option for the patient.

Dr Carole Longson, health technology evaluation centre director at NICE, commented: “NICE is pleased to five the green light to dexamethasone intravitreal implant for some people with diabetic macular oedema in preliminary recommendations.

“The condition affects around 189,000 people with diabetes in the UK, 39% of whom are eligible for this treatment.”

The cost of a 700-microgram implant and applicator is £870, with one implant administered every six months in the affected eye and up to seven implants may be given. 

Ozurdex is injected into the eye once every six months and works by suppressing inflammation and preventing oedema forming in the eye. This reduces leaking from blood vessels and restrains the release of inflammatory compounds that cause damage to the eye.

The eye indication was approved for DMO in the EU in September of last year, setting it up as competition against Novartis' blockbuster eye drug Lucentis (ranibizumab) as well as Bayer'd Eylea (aflibercept), which both have licences for DMO.

Article by
Kirstie Pickering

20th February 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics